From the March issue: PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State https://t.co/EyDrssnig8
By Shane Killarney, @kcw00d, and colleagues @Duke_PCB@DukeCancer
I'll see if someone else from PIRL wants to do a full thread on our NUT carcinoma paper but will highlight two figures: (a) shotgun immunopeptidomics shows mostly PRAME derived MHC ligands in NUT carcinoma (b) T-cells with PRAME/aCD3 TCR bispecifics kill NUT carcinoma cell lines
🧬A new study by the Wang Lab uncovers how NUP98 oncofusion condensates selectively recruit transcriptional coactivators, revealing new insights into oncogene activation. @DukeCancer
Check it out here: https://t.co/ygMUuenhOe🧪
We are proud to recognize 52 finalists for the 2025 Hertz Fellowship, selected from a talented group of +1,000 applicants across 27 universities. Wishing them all the best in the final round!🎉 https://t.co/Vzwe8Grqx3
#HertzFellows#Fellowships#Scholarships#STEM#Science
New online! Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck https://t.co/UYdCE8sr1p
gαмє тняєє.
Back at home and in our @nmdp_org jerseys 😎 All jerseys are for sale through the link in our bio with 💯 of the proceeds going towards NMDP 🫶
🆚 VMI
🏟️ Greenwood Field
⌚️ 4:00 pm
📊 https://t.co/ygsSJZBOAl
🎥 https://t.co/a5WmRUCKL5
👕 https://t.co/H1ixUj9nKb
When Emily was diagnosed with a rare NUT carcinoma in 2019, she was told the average life expectancy was six to nine months. Genomic testing identified a treatment Emily is still using today, but she wasn't able to access it until her condition deteriorated.
12,000 years from now, when our civilization is a distant memory, there will be a patch of synthetic leather buried deep under millennia of sediment. And that little piece of unrotten plastic will still remember getting kicked by Tyler Adams.
Overview of management of NUT carcinoma in Germany @LungCaJournal. Most had BRD4-NUTM1 fusion, most common initial therapy is surgery, ifosfamide-based regimens associated with better PFS. Initial misdiagnosis an issue in 31 % of the cases.
https://t.co/e1NydKc2En
Our team at @RareCancerRF is inspired and driven every day by @MarkLaabs's urgent vision for all rare cancer patients. You can learn more in @CancerTodayMag https://t.co/r9v8LZLxDY